About Mithradote Bio
Mithradote Bio is a company based in San Diego (United States) founded in 2023 by Sophia Lee. Mithradote Bio has raised $1 million across 1 funding round from investors including Taho Pharma and Vickers Venture Partners. Mithradote Bio offers products and services including M-101. Mithradote Bio operates in a competitive market with competitors including IgGenix, Tempero Bio, Globin Solutions, Sobrera and metaLead Therapeutics, among others.
- Headquarter San Diego, United States
- Founders Sophia Lee
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Mithradote Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1 M (USD)
in 1 rounds
-
Latest Funding Round
$1 M (USD), Seed
Oct 02, 2024
-
Investors
Taho Pharma
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mithradote Bio
Mithradote Bio offers a comprehensive portfolio of products and services, including M-101.
Sublingual pan-antidote to reverse effects of benzodiazepines in drink spiking.
Funding Insights of Mithradote Bio
Mithradote Bio has successfully raised a total of $1M through 1 strategic funding round. The most recent funding activity was a Seed round of $1 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mithradote Bio
Mithradote Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Taho Pharma and Vickers Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth-stage venture capital is invested in Singapore and China.
|
Locked | Locked | Locked | |
|
Company developing CNS and oncology drugs through their proprietary transepithelial drug delivery systems
|
Locked | Locked | Locked |
Investor details for Mithradote Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mithradote Bio
Investment portfolio details for Mithradote Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mithradote Bio
Detailed financials for Mithradote Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mithradote Bio Comparisons
Peer comparison for Mithradote Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mithradote Bio
Mithradote Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IgGenix, Tempero Bio, Globin Solutions, Sobrera and metaLead Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| Locked | Locked | Locked |
Therapeutics for substance use disorders, including opioid-related conditions, are developed.
|
|
| Locked | Locked | Locked |
Antidotal therapies for human poisonings are developed using neuroglobin technology.
|
|
| Locked | Locked | Locked |
Drugs for alcohol use disorders are developed by Sobrera.
|
|
| Locked | Locked | Locked |
Next-generation medications against metal poisoning are developed.
|
Detailed competitors of Mithradote Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mithradote Bio
Complete news archive for Mithradote Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mithradote Bio
Mithradote Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Mithradote Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sophia Lee is the current CEO of Mithradote Bio. They have also founded this company.
Mithradote Bio is a funded company, having raised a total of $1M across 1 funding round to date.
Mithradote Bio was founded in 2023 and is based in San Diego, United States. Operations focus on the biotechnology sector, where medication is developed to counter drug-facilitated sexual assault. A lead product, M-101, is offered as a sublingual pan-antidote targeting benzodiazepines, Z drugs, and other GABA agonists. The company addresses preventive healthcare needs through targeted pharmaceutical solutions.
Mithradote Bio's top competitors include IgGenix, Tempero Bio and Globin Solutions.
Mithradote Bio offers M-101.
Mithradote Bio has 2 investors. Key investors include Taho Pharma, and Vickers Venture Partners.